Hechi

Researchers are evaluating the safety and effectiveness of intravenous urokinase compared to intravenous alteplase in treating acute ischemic stroke (AIS) within 6 hours of symptom onset. Alteplase is currently the recommended treatment within 4.5 hours but is costly, while urokinase is more affordable. Existing evidence about urokinase's effectiveness and safety is mixed, with some studies suggesting it may improve blood flow and reduce bleeding risks compared to alteplase, while others indicate it may be less effective. This study aims to provide real-world data on these treatments across multiple centers in China. The study involves two treatment groups receiving either intravenous urokinase or intravenous alteplase. Both drugs are administered through the veins. The study will explore different dosing levels of urokinase and analyze associated risk factors. Alteplase serves as the active control to compare outcomes and economic effects. This nationwide, prospective study will observe and analyze patients receiving these treatments to assess their impact on AIS. Participants will be assessed through imaging to confirm stroke type and exclude hemorrhage. Researchers will monitor functional outcomes using the modified Rankin Scale at 90 days post-treatment, tracking good recovery levels. Data on safety, adverse reactions, and mortality will be collected, along with economic evaluations. Participants must be followed for at least 90 days to evaluate long-term outcomes and treatment safety.